Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the TD Cowen 46th Annual Health Care Conference and Leerink Partners Global Healthcare Conference in Boston and Miami, respectively. Gaurav Shah, M.D., Chief Executive Officer, will take part in a fireside chat and manag.

Business Wire • Feb 23, 2026

Rocket Pharmaceuticals, Inc. (RCKT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Rocket Pharmaceuticals, Inc. (RCKT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 14, 2026

3 cheap stocks that could turn $1,000 into $10,000

At the start of 2025, the stock market appeared unstable as most major assets were, seemingly, very overvalued. Despite this, there was no shortage of opportunities for savvy investors to find undervalued, cheap stocks that enabled them to turn a $1,000 into $10,000 of profit.

Finbold • Jan 14, 2026

Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the 44th Annual J.P. Morgan Healthcare Conference, in San Francisco. Gaurav Shah, M.D., Chief Executive Officer, is scheduled to present on Wednesday, January 14, at 11:15 a.m. PT and host investor meetings throughout th.

Business Wire • Jan 5, 2026

Rocket Pharmaceuticals: Deep Dislocation Offers Asymmetric Upside On LAD-I Approval And Amended Danon Program

Rocket Pharmaceuticals is rated Buy with a $17 price target, reflecting a deep disconnect between intrinsic value and current valuation. RCKT's bullish thesis hinges on a high-probability LAD-1 approval in March 2026 and the pivotal Danon's disease trial resuming with an amended, safer protocol. Risk-adjusted DCF values Danon's and LAD-1 programs at ~$700M, far exceeding the current $151M EV, even under conservative or bear-case assumptions.

Seeking Alpha • Dec 26, 2025

Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the 8th Annual Evercore Healthcare Conference in Miami. Gaurav Shah, M.D., Chief Executive Officer, will take part in a fireside chat on Tuesday, December 2, at 7:55 a.m. ET and host investor meetings. A webcast of the p.

Business Wire • Nov 25, 2025

Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the third quarter ending September 30, 2025. “During the third quarter, we maintained disciplined execution and sharpened our strategic focus on Rocket's AAV cardiovascular gene therapy portfolio,” said Gaurav Sha.

Business Wire • Nov 6, 2025

ROCKET ALERT: Bragar Eagel & Squire, P.C. is Investigating Rocket Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Rocket (RCKT) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in  Rocket securities between February 27, 2025 to May 26, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.

GlobeNewsWire • Oct 23, 2025

RCKT Stock Up as FDA Accepts Resubmitted BLA for Gene Therapy

Rocket Pharmaceuticals surges as the FDA accepts its resubmitted BLA for Kresladi, a gene therapy targeting the rare LAD-I disorder.

Zacks Investment Research • Oct 15, 2025

FDA Acceptance Of Rocket Pharmaceuticals' Lead Gene Therapy Application Reestablishes Momentum For Stock

On Tuesday, the U.S. Food and Drug Administration (FDA) accepted Rocket Pharmaceuticals, Inc.'s (NASDAQ:RCKT) resubmission of the Biologics License Application (BLA) for Kresladi (marnetegragene autotemcel; marne-cel), a lentiviral vector (LV)-based investigational gene therapy for severe Leukocyte Adhesion Deficiency-I (LAD-I).

Benzinga • Oct 14, 2025